Technology

Israel opened its first national pavilion at Morocco’s Marrakech Air Show, joined by Israel’s top military contractors.

Israel’s Ministry of Defence says it is participating for the first time in a defence exhibition in Morocco, as it announced its first-ever national pavilion at the Marrakesh Air Show 2026.

“This marks Israel’s first official participation in the defence exhibition held in Morocco since the signing of the Abraham Accords”, Israel’s Defence Ministry said in a statement on Thursday.

The ministry said eight Israeli defence companies exhibited “advanced, combat-proven technologies at the show” in Marrakesh, which runs until Saturday.

The Marrakech Air Show, taking place from October 7 to October 10 this year at the Marrakech Royal Moroccan Air Force Base, is organised every two years and is meant for civil and military aeronautics and space industries to highlight their latest offerings.

“Israel’s three major defence industries, Elbit Systems, IAI, and Rafael, also exhibited, presenting solutions across the air, land, sea, space, intelligence, cyber, and digital domains,” it said.

The announcement is the latest sign of increasing ties between the Arabic-speaking North African country and Israel, since the two established ties in 2020 as part of the US-backed Abraham Accords.

Last month, Israel and Morocco agreed to upgrade their diplomatic ties, including elevating their respective missions to embassies and appointing ambassadors to both countries.

The move followed a meeting between the two countries’ foreign ministers, hosted by the US ambassador to the United Nations, Mike Waltz, on the sidelines of the United Nations General Assembly in New York.

They also agreed to expand air travel, including by reinstating direct flights operated by carriers from both nations, and confirmed plans for high-level bilateral visits in the coming months.

Morocco is also one of the five countries that have pledged to send troops to Gaza, under the US-backed International Stabilization Force (ISF) as part of US President Donald Trump’s so-called Board of Peace.

Visa probe also targets universities for allegedly exploiting international students to reduce US wage costs.

The United States government is suspending several major tech companies, including Adobe and Microsoft, from a programme that gives skilled foreign workers a path to permanent residency amid allegations of fraud.

This comes amid pressure by the White House on companies to hire more Americans. “Our message to Microsoft is: You’re a great American company, but you’ve got to hire great American workers,” US Vice President JD Vance said at a news conference on Thursday.

Vance added that the Redmond, Washington-based tech giant laid off 6,000 American workers, while obtaining 6,300 H-1B visas and almost 3,000 green cards.

“You cannot lay off American workers and replace them with foreign indentured servants,” Vance said.

“When someone comes in, they are completely subordinate to that company. If they lose that job, they have to leave the country.”

Across the tech sector, there have been more than 131,000 layoffs in 2026 alone, according to Layoffs.fyi, which tracks job cuts across the tech and startup industries.

Neither Adobe nor Microsoft responded to Al Jazeera’s request for comment.

Secretary of Labor Keith Sonderling also said that several major information technology firms will be suspended from the programme as well. Among them are Indian tech giants Infosys and Tata Consultancy Services.

The Department of Labor also said it had uncovered $22bn worth of visa fraud.

“Today we are protecting something far more valuable than any dollar amount. We are protecting the American worker,” Sonderling said.

During the news conference, officials also announced a crackdown on alleged J-1 visa fraud involving nine universities, including MIT, Harvard, Yale, Stanford and Cal State, amid allegations that they brought in international students to undercut US wages. A J-1 visa allows foreign nationals to enter the US temporarily for education or cultural programmes. Universities use these visas to bring in international PhD candidates or scholars.

Vance claimed that when schools employ an American as a researcher, that person earns $20,000 more than someone brought in under a J-1 visa.

Al Jazeera asked for data supporting this claim, but the White House did not respond.

Microsoft’s stock slumped 7.5 percent on the heels of the news, while Adobe was up 4 percent in midday trading on Thursday.

Scientists honoured for solving mystery of asymmetric ‘mirror image’ molecules that has helped in manufacture of pharmaceuticals.

Scientists Henri Kagan and Kenso Soai have won the 2026 Nobel Prize in Chemistry for solving a longstanding riddle of asymmetric “mirror image” molecules, a discovery hugely important for pharmaceutical manufacturing.

The Royal Swedish Academy of Sciences said on Wednesday the pair – Kagan, 95, from France; and Soai, 76, from Japan – were honoured “for the discovery of nonlinear effects and autocatalysis in asymmetric organic synthesis”.

Their findings showed how chemical reactions can be driven to favour a single molecular mirror image, work that has been key for chemists who design reactions for the manufacture of pharmaceuticals.

Many of the molecules essential to life exist in two forms that are mirror images of each other, like left and right hands. Yet living organisms almost exclusively use only one version, a phenomenon known as “homochirality” – from the Greek word for hand – that has puzzled chemists for more than a century.

“The left-handed version of the drug can have one effect, and the right-handed version can have another effect, and then we need methods for selectively preparing them,” said Peter Somfai, a member of the Nobel Committee for Chemistry.

“In developing such methods, the findings of this year’s laureates are important. They provided powerful tools for that,” he said.

Heiner Linke, chair of the committee, said the two scientists provided “a solution to a chemical mystery that is over a century old: how homochirality can emerge spontaneously”, calling the chemical reactions they developed “spectacular”.

‘Most exciting day’

Soai, speaking by phone to the Nobel Prize news conference, said he had been out shopping when he received the news.

“This is the most exciting day in my life, I am very glad to share this prize with Professor Henri Kagan,” he added.

Last year’s chemistry award went to scientists Susumu Kitagawa, Richard Robson and Omar Yaghi for the development of so-called metal-organic frameworks, molecular constructions that can help tackle challenges such as climate change and lack of freshwater.

The chemistry Nobel is always the third prize to be awarded during Nobel week, following those for medicine and physics.

The literature laureate will be revealed on Thursday, while the keenly anticipated peace prize is due on Friday.

Established in the will of Swedish inventor and businessman Alfred Nobel, the prizes for achievements in science, literature and peace have been awarded since 1901, with a few interruptions mostly due to the world wars.

Nobel, a chemist by trade, amassed huge wealth in the 19th century from inventions primarily tied to warfare, most notably dynamite. The economics prize is a later addition funded by the Swedish central bank.

TA419 hackers used deceptive tactics, impersonating real figures like a former White House AI official

Chinese hackers have been impersonating artificial intelligence (AI) experts in the United States, including a former government official, according to a new report from cybersecurity firm Proofpoint.

The report, released on Thursday, found that in July, a China-aligned hacking group called TA419 targeted a slate of US policy experts by impersonating prominent figures, including Lynne Edwards Parker, the former principal deputy director of the White House Office of Science and Technology Policy.

The hackers, who had been operating since April 2025, first sent otherwise harmless-looking emails intended to engage a target, such as requests to join an “AI Policy Advisory Committee”, and, once they responded, the target would be sent to a fake login page designed to steal their credentials.

The targets included policy experts at think tanks, defence contractors, universities and law firms in both the US and Japan.

The report used a technique that creates a fake browser pop-up window inside a legitimate webpage that mimics an authentic-looking sign-in prompt to deceive victims and make it harder for them to realise they are handing over their information to hackers.

Proofpoint did not specifically name the targets hacked, but the Reuters news agency was able to confirm at least one of them as Alex Engler, a former White House official who now heads the Penn Center on Media, Technology, and Democracy.

Engler told Reuters that he got one of the emails, but after checking with industry colleagues, he discovered that he had received the email from an impersonator.

In February, the same group was behind the impersonation of a “prominent” Anthropic employee in efforts to target AI policy experts. The cybersecurity firm behind the report believes that the group will continue to target think tanks and other policy experts and will continue to use the identity of real-world experts to do it.

Parker did not respond to Al Jazeera’s request for comment.

A medicine injected just twice a year could transform the fight against HIV.

In a 2024 clinical trial involving more than 2,000 young women in South Africa and Uganda, no participants who received lenacapavir contracted HIV.

Developed by United States pharmaceutical company Gilead Sciences, the injectable drug can be used to prevent HIV.

“It’s the most innovative tool that has reached the HIV arena for the last decade, because it’s the closest we have [to] a vaccine,” Carlota Baptista da Silva, global HIV lead at Doctors Without Borders (known by its French initials, MSF), told Al Jazeera.

The World Health Organization has recommended the long-acting injectable as an additional form of pre-exposure prophylaxis, or PrEP – medicine to reduce the risk of getting HIV.

But the arrival of the drug comes at a challenging juncture in the global fight against HIV.

International funding for HIV fell 18 percent in 2025, to $7.3bn, its lowest level in nearly two decades, according to the United Nations programme on HIV/AIDS (UNAIDS). The squeeze has already hit prevention programmes: The number of people receiving medicine to reduce risk fell from 1.4 million in 2024 to 1.1 million in 2025.

That makes the arrival of a highly effective, twice-yearly prevention option significant. The question of who can access it is now more urgent.

For MSF, the scientific question has largely been answered: lenacapavir can prevent HIV with remarkable efficacy.

The fight now is whether the rules governing manufacture, price and supply will allow that scientific breakthrough to reach the people who need it.

Why some countries are excluded

In the United States, lenacapavir costs about $28,000 per person annually. Generic versions are expected to cost about $40 a year.

A generic version is a copy of the original drug made by another manufacturer after the patent holder licenses the technology. It contains the same active ingredient, but it can be produced and sold at a much lower price.

In June 2025, the US Food and Drug Administration (FDA) approved lenacapavir for HIV prevention, giving people the option of an injection twice a year. But in several low- and middle-income countries, access to cheaper versions is not expected at scale until 2027.

Gilead is supplying its own version of lenacapavir at no profit for programmes supported by the Global Fund and the US President’s Emergency Plan for AIDS Relief (PEPFAR), with rollouts under way in countries including South Africa, Kenya, Zambia, Nigeria and Eswatini.

These are not the cheaper generic versions expected to cost about $40 per person a year. Gilead has licensed six manufacturers to produce those, with large-scale generic rollout expected in 2027.

At least 26 middle-income countries are excluded from Gilead’s generics agreement, MSF says, including countries with rising HIV infections and some that helped test the drug. Among them are Brazil, Mexico, Argentina and Peru.

“People should not really help generate the evidence for breakthrough medicine and then find that their country is excluded from affordable generic access,” da Silva said.

According to MSF, countries excluded from the licence accounted for close to 23 percent of new HIV infections globally in 2023.

Gilead has since announced a separate agreement with the Pan American Health Organization, creating an access pathway for 14 Latin American and Caribbean countries outside its generic licensing territory, including Brazil, Mexico, Argentina and Peru.

MSF argues that leaves those countries dependent on Gilead rather than able to automatically buy the cheaper generics.

MSF says it still cannot buy the drug

For more than a year, MSF says it has sought permission to purchase lenacapavir directly from Gilead for its medical programmes, without demanding a discounted price.

“Despite those requests, Gilead has not allowed MSF to purchase this medicine directly,” da Silva said.

That matters particularly in humanitarian emergencies, she argues. People displaced by conflict or disaster may struggle to take a prevention pill every day, while sexual violence and other vulnerabilities can increase the risk of HIV.

Daily PrEP pills are already available as an alternative to the injection. But unlike lenacapavir, they need to be taken consistently to provide protection. An injection offering six months of protection could be particularly valuable.

“People living through conflict [and] humanitarian crises cannot be the last in line for medical innovation,” da Silva said.

Gilead declined Al Jazeera’s request for an interview due to scheduling constraints.  In its emailed statement, it said its access strategy combines no-profit supplies, royalty-free licensing and regional agreements. It didn’t reply to questions about why it won’t sell its drug to MSF, or why certain countries were excluded from its generics agreement.

The company plans to provide enough lenacapavir for up to three million people through 2028 as generic manufacturers scale up production, with large-scale generic rollout expected in 2027.

MSF says that is nowhere near the scale required, pointing to projections that close to 20 million people worldwide need access to PrEP to substantially reduce new HIV infections. That includes all forms of PrEP, not just lenacapavir.

But countries left outside Gilead’s generic licensing deal may have another option.

Can governments bypass the patent barriers?

World Trade Organization (WTO) rules allow governments, in some cases, to bypass a drug company’s patent so cheaper versions of a medicine can be made or imported without the company’s permission.

They can also authorise government use of patents and challenge patents they consider weak or unjustified. The 2001 Doha Declaration affirmed WTO members’ right to use such safeguards to protect public health.

Brazil has used them before in the fight against HIV. In 2007, after negotiations with pharmaceutical company Merck over the price of the HIV drug efavirenz failed, Brazil issued a compulsory licence allowing it to access cheaper generic versions of the medicine.

Nearly two decades later, activists are urging Brazil to consider using those powers again for lenacapavir if patent barriers prevent affordable generic access.

MSF says governments excluded from Gilead’s licence could consider those same legal safeguards for lenacapavir, including compulsory licensing, government-use authorisations and challenges to patents.

It is also calling on Gilead to ensure its agreements with generic manufacturers do not prevent them from supplying countries where patent barriers have been removed through such measures.

For MSF, the stakes go beyond lenacapavir. The way the drug is made available could determine whether one of the greatest advances in HIV prevention in decades reaches people based on need, rather than where they live or what their health systems can afford.

“For a humanitarian medical organisation, we should not have to spend more than a year trying to find a way to buy a WHO-recommended medicine,” da Silva said.

Exports jump 83.5 percent to top $120bn for the first time amid ferocious semiconductor demand.

South Korea’s exports have surged to a monthly record amid explosive demand for chips used to power artificial intelligence.

Exports jumped 83.5 percent year-on-year to $120.9bn in September, eclipsing the previous monthly record of $102.25bn set in June, preliminary customs figures showed on Thursday.

Chip shipments accounted for nearly half of exports, soaring more than 260 percent to $60.3bn, according to data from the Korea Customs Service.

Total exports from January through September hit $814.5bn, exceeding those for all of 2025, when exports reached a record $709.7bn.

During the first nine months of the year, the country recorded a trade surplus of $49.85bn.

“This is a valuable achievement that once again demonstrates the strength of our industries and companies, and is thanks to the sweat and efforts of our entrepreneurs who have competed fiercely in the global market,” said Kim Jeong-kwan, South Korea’s minister for trade and industry, in a statement.

“While we expect to achieve $1 trillion in annual exports, the strengthening of global protectionism and tensions in the Middle East remain major variables affecting our exports,” Kim said.

South Korea’s economy has been running red-hot this year amid a global shortage of memory chips used in AI.

Asia’s fourth-largest economy is home to one of the world’s largest semiconductor industries, led by top memory chip makers SK Hynix and Samsung Electronics.

SK Hynix and Samsung Electronics together control roughly 80 percent of the global market for high-bandwidth memory and 60 percent of the market for dynamic random-access memory, according to Counterpoint Research.

South Korea’s nominal gross domestic product (GDP) growth hit a five-decade high in the April-June quarter, skyrocketing 26.4 percent year-on-year.

South Korea’s Ministry of Finance and Economy has forecast real GDP to grow 3 percent in 2026, which would be the strongest performance since 2017, excluding the outlier years of the COVID-19 pandemic.

The AI boom has also propelled the country’s stock market into the ranks of the best-performing bourses this year, with the benchmark Kospi rising nearly 60 percent.

America.gov for now functions like a chatbot comparable to ChatGPT or Claude, pointing users to official gov’t websites.

The administration of United States President Donald Trump has launched a new website called America.gov aimed at simplifying access to government information.

The website functions much like a chatbot comparable to OpenAI’s ChatGPT and Anthropic’s Claude and points users to official government sources for questions such as passport renewals.

The president announced the new site on Tuesday alongside several Cabinet officials, including Secretary of State Marco Rubio and Transportation Secretary Sean Duffy.

In a speech, the president claimed that the website would not store user information and used the opportunity to tout simplified access to information about elections and applications for citizenship.

The site is powered by Google’s Gemini AI and xAI’s Grok, according to the chief design officer, Joe Gebbia.

The executive order announcing the new site calls it “a unified digital front door to the Federal Government for every individual in the United States seeking Federal information or services”.

It also says the site will provide “an entry through which an individual may sign in, communicate in plain language, receive accurate answers, and, where authorized and technically available, complete Government transactions without being required to navigate the websites of multiple agencies.”

White House officials told Al Jazeera that the website will abide by the security protocols of the government agency users inquire about, and it will be retained by those agencies and not America.gov, for example, Medicare.

Al Jazeera tested the answers the website provides to see how they align with the president’s views.

When asked “who is the fake news?”, it said, “I don’t label news outlets or comment on media.” When asked who won the 2020 presidential election, it said Joe Biden. When asked whether the department in which Pete Hegseth is secretary is the Department of Defense or Department of War, it said, “Department of Defense (DoD). That is still the name in statute until Congress changes it.”

When asked about obtaining specific records, such as individual tax information, citizenship records, political donations or Securities and Exchange Commission filings, it directed users to the government websites that provide that data for individuals.

However, in the presentation announcing the new site, Rubio showed that, in the future, the website may be able to help Americans apply for passports directly through the site and even take and upload their passport photos.

The website was created in coordination with the National Design Studio, which is part of the Executive Office of the President and was established by Trump in August 2025.

DEVELOPING STORYDEVELOPING STORY,

OpenAI has cancelled the release of its latest AI model over safety concerns, according to media reports.

The move to scrap the release of GPT-6.1 Astra, reported by the Wall Street Journal and CNN on Monday, comes amid heightened concerns about AI’s potential to do catastrophic harm following a slew of incidents involving AI agents going rogue.

More to follow…

California jury finds Apple infringed two Taction patents but did not willfully violate them; Apple plans to appeal.

Apple has been ordered to pay more than $5.7bn for using patented technology from Taction Technology to power haptic feedback, the vibrations users feel when they receive a notification or press a button.

A jury in federal court in the Southern district of California found that the iPhone maker infringed two patents owned by the San Diego-based company.

“We’re happy the jury found for Taction and vindicated its patent rights,” said Taction attorney Lance Yang following the verdict on Friday.

The verdict is the culmination of a legal battle that began in 2021, when Taction first filed its lawsuit against Apple. In 2023, a federal judge ruled that Apple had not infringed Taction’s patents, but an appeals court revived the case last year.

“Apple is capitalising on Taction’s innovation and success by selling devices that infringe Taction’s patents. Apple is utilising Taction’s patented inventions without license or authority from Taction. Taction has brought this action to remedy Apple’s infringement,” Taction said in the original 31-page complaint.

It also claimed that Apple “at a minimum believed there was a high probability that the accused products were covered by Taction’s patents, but willfully blinded itself to Taction’s patents and the infringing nature of the Accused Products”.

The jury, however, found that Apple did not wilfully infringe the patents.

Apple said it plans to appeal the verdict.

“Apple’s Taptic Engine is fundamentally different from Taction’s technology, which Taction’s own testing of Apple’s products confirmed during trial,” Apple said in response.

The verdict comes at a pivotal moment for the company, amid transitions in its C-suite. In September, John Ternus took over as CEO from Tim Cook, who led Apple for 15 years. The leadership change comes as the Cupertino, California-based tech giant lags behind other major technology companies in rolling out its artificial intelligence products.

Apple shares fell on Monday, declining about two percent as trading got underway.

Private dinner will be the first one-on-one meeting between the two men, according to reports.

Anthropic CEO Dario Amodei is set to dine one-on-one with US President Donald Trump at the White House.

The meeting on Sunday evening, confirmed by Trump, comes after months of open conflict between the artificial intelligence startup and the Trump administration.

The private dinner would be the first one-on-one meeting between the two men, according to US media, including Axios, which first reported the dinner.

Trump confirmed the dinner on Sunday evening and reaffirmed his stance against slowing the pace of AI development.

Trump also reiterated his belief that new regulations would open the door for China to outpace the United States in AI advancement.

Although he acknowledged Amodei’s concern that going too fast on artificial intelligence could expand risks, Trump said it was more important for the US to maintain a technological edge over China.

“We’re about maybe a year and a half up on China,” Trump told Fox News while attending the Presidents Cup golf tournament in Illinois.

“We’re leading, and we’re building tremendous, trillions of dollars’ worth of places. And why should we give that up?”

The meeting comes two days after a federal appeals court upheld the Pentagon’s decision to classify Anthropic as a “supply chain risk”, which prohibits the US military from using its models.

The startup was sanctioned by the Trump administration after refusing in February to allow its tools to be used for fully autonomous weapons or domestic mass surveillance.

Trump also badmouthed Amodei, saying he was trying to be “a perfect little angel” after the Anthropic chief called for a pause in AI development.

Amodei was absent from the state dinner held for Chinese President Xi Jinping on Thursday, attended by AI industry leaders, including Amodei’s rival Sam Altman of OpenAI.

Despite mounting calls to slow down AI development due to the risk of losing control of the technology, the US government believes that the sector’s major players – OpenAI, Anthropic, Google, and Meta – cannot afford to slow down for fear that China will gain the upper hand.

Trump and Mike Johnson, the speaker of the House of Representatives, are set to meet with leading AI executives on Tuesday.